NEWS HIGHLIGHTSMedia Articles Related to Reminyl (Galantamine)
Alzheimer's Disease
Source: MedicineNet Immunizations Specialty [2017.06.01]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 12:00:00 AM
Last Editorial Review: 6/1/2017 12:00:00 AM
Dementia, Alzheimer's Disease, and Aging Brains
Source: MedicineNet Hydrocephalus Specialty [2016.08.01]
Title: Dementia, Alzheimer's Disease, and Aging Brains
Category: Slideshows
Created: 12/3/2009 10:07:00 AM
Last Editorial Review: 8/1/2016 12:00:00 AM
Alzheimer's Disease Symptoms & Early Diagnosis
Source: MedicineNet memantine Specialty [2016.07.27]
Title: Alzheimer's Disease Symptoms & Early Diagnosis
Category: Slideshows
Created: 9/21/2015 12:00:00 AM
Last Editorial Review: 7/27/2016 12:00:00 AM
Caring for Someone With Alzheimer's Disease
Source: MedicineNet memantine Specialty [2016.05.16]
Title: Caring for Someone With Alzheimer's Disease
Category: Slideshows
Created: 2/16/2010 2:51:00 PM
Last Editorial Review: 5/16/2016 12:00:00 AM
7 Alzheimer's Disease Stages and Symptoms
Source: MedicineNet Advance Medical Directives Specialty [2016.05.12]
Title: 7 Alzheimer's Disease Stages and Symptoms
Category: Diseases and Conditions
Created: 7/30/2014 12:00:00 AM
Last Editorial Review: 5/12/2016 12:00:00 AM
Published Studies Related to Reminyl (Galantamine)
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for
the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or
The prediction of response to galantamine treatment in patients with mild to
moderate Alzheimer's disease. [2014]
The prediction of efficacy in long-term treatment of acetylcholinesterase
inhibitors (AChEIs) is a major clinical issue, although no consistently strong
predictive factors have emerged thus far... Patients who show improvement of episodic
memory function during the first 4 weeks of galantamine administration may be
likely to particularly benefit from galantamine treatment.
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Clinical Trials Related to Reminyl (Galantamine)
Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a
subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P.,
U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fed conditions.
Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a
subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P.,
U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fasting conditions.
Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition [Completed]
Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition [Completed]
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to demonstrate that the change of attention measure is
correlated with the changes of caregiver's burden after treatment with galantamine.
|
